Estradiol/norethisterone
Estradiol/norethisterone (E2/NET), tentative brand name Netagen or Netagen 403, was a combination of estradiol (E2), an estrogen, and norethisterone (NET), a progestin, which was studied as a birth control pill to prevent pregnancy in women.[1][2][3][4][5] It was taken by mouth and contained 4 mg micronized E2 and 3 mg NET per tablet.[2][3] The medication was developed by Novo Pharmaceuticals in Denmark and was never marketed.[1][2][3]
 Estradiol | |
 Norethisterone | |
| Combination of | |
|---|---|
| Estradiol | Estrogen |
| Norethisterone | Progestogen; Progestin |
| Clinical data | |
| Other names | E2/NET; Netagen; Netagen 403 |
| Routes of administration | By mouth |
| Drug class | Estrogen; Progestin; Progestogen |
| Legal status | |
| Legal status |
|
Two related formulations were Netagen 423 (4 mg estradiol, 2 mg estriol, 3 mg norethisterone) and Netasyn (50 μg ethinylestradiol, 3 mg norethisterone), were also studied but never marketed.[1][3][4]
See also
References
- Fruzzetti F, Bitzer J (January 2010). "Review of clinical experience with estradiol in combined oral contraceptives". Contraception. 81 (1): 8–15. doi:10.1016/j.contraception.2009.08.010. PMID 20004267.
- Astedt B, Svanberg L, Jeppsson S, Liedholm P, Rannevik G (January 1977). "The natural oestrogenic hormone oestradiol as a new component of combined oral contraceptives". Br Med J. 1 (6056): 269. doi:10.1136/bmj.1.6056.269. PMC 1604185. PMID 319864.
- Astedt B, Jeppsson S, Liedholm P, Rannevik G, Svanberg L (September 1979). "Clinical trial of a new oral contraceptive pill containing the natural oestrogen 17 beta-oestradiol". Br J Obstet Gynaecol. 86 (9): 732–6. doi:10.1111/j.1471-0528.1979.tb11276.x. PMID 387069.
- Samsioe G, Skryten A, Silfverstolpe G (1983). "Oral contraception with a nonalkylated estrogen component. Effects on lipid metabolism". Gynecol. Obstet. Invest. 15 (5): 275–82. doi:10.1159/000299421. PMID 6852647.
- Skouby SO, Jensen BM, Kühl C, Mølsted-Pedersen L, Svenstrup B, Nielsen J (July 1985). "Hormonal contraception in diabetic women: acceptability and influence on diabetes control and ovarian function of a nonalkylated estrogen/progestogen compound". Contraception. 32 (1): 23–31. doi:10.1016/0010-7824(85)90113-1. PMID 4053603.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.